MAPT and Alzheimer disease: Importantly, we utilized a rigorous, objective measurement of sleep duration using wrist actigraphy (i.e., as opposed to relying on self‐report), we adjusted for daytime napping, and our results held across stages of tau progression in AD (i.e., Braak stage groupings), lending robustness to the observed moderating effects of nocturnal sleep duration.